Last reviewed · How we verify
NJOY e-cigarette
At a glance
| Generic name | NJOY e-cigarette |
|---|---|
| Sponsor | Milton S. Hershey Medical Center |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Pharmacokinetics and Pharmacodynamics of Nicotine With Use of Standardized Research Electronic Cigarette (SREC) (NA)
- Impact of Cigarette and E-cigarette Menthol Regulation on Current Smokers of Menthol Cigarettes (NA)
- Adaptive Use of Nicotine Substitution to Maintain Smoking Reduction/Abstinence in Nicotine Responders (PHASE3)
- Assessing E-Cigarettes for Tobacco Harm Reduction in the Context of Lung Cancer Screening (NA)
- Harm Reduction for Smokers With Mental Illness (NA)
- MRI and Biological Markers of Acute E-Cigarette Exposure in Smokers and Vapers (NA)
- E-cigarette Switching Older Adults (NA)
- Electronic Cigarette-derived Oxidants and Cardiopulmonary Effects (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NJOY e-cigarette CI brief — competitive landscape report
- NJOY e-cigarette updates RSS · CI watch RSS
- Milton S. Hershey Medical Center portfolio CI